Excellent video!
Some highlights after a first pass, many other great details I didn't write down.
Dr Lalezari at 17:27
"The data that we're getting in . . . the clinical benefit is quite striking."
Dr Lalezari @ 19:58, re the TNBC results: "I was stunned."
Dr Lalezari @22:00 "the common denominator among the (TNBC) survivors: Individuals who had been on Leronlimab, had induced a protein cvalled PD-L1...and who subsequently received a checkpoint inhibtor which blocked the action of PD-L1. 100% of the women who did induce PD-L1 and subsequently received a checkpoint inhibitor are alive today."
Dr Lalezari @ 27:55 "Leronlimab has been given to 1600 patients or so, and it's been very well tolerated . . .and is not associated with any sort of dominant safety or toxicity issues . . .which is not something you can really say about any other cancer drug."
Dr Lalezari @ 28:12 "We're seeing a signal . . .retrospectively that the drug appears to be working on both triple negative breast cancer and in colorectal cancer . . and in particular , in the patients who happen to get a checkpoint inhibitor, we're seeing evidence of sustained remission. . . which is unheard of in a patient with lung and brain metastasis."
Dr Lalezari @ 28:37 "The onus on Cytodyn now . . .and the reason I feel enormous pressure everyday . . .is that we have to prospectively confirm this . . . prospectively confirm both that Leronimab is disrupting the micro environment and causing this PDL1 induction and that providing the patients with a checkpoint inhibitor provides them with significant clinical benefit. And if we do that, it's a game changer."
The host @ 29:25 "You're on the precipice here of some major things."
Dr Lalezari: "I think precipice is the right word."
30:10 re colorectal cancer study "We have a bunch of sites actively enrolling now."
31:40 glioblastoma is "a bit of a bankshot"
Finally at the end, he thanks the shareholders.
Nice to finally hear something!
Some highlights after a first pass, many other great details I didn't write down.
Dr Lalezari at 17:27
"The data that we're getting in . . . the clinical benefit is quite striking."
Dr Lalezari @ 19:58, re the TNBC results: "I was stunned."
Dr Lalezari @22:00 "the common denominator among the (TNBC) survivors: Individuals who had been on Leronlimab, had induced a protein cvalled PD-L1...and who subsequently received a checkpoint inhibtor which blocked the action of PD-L1. 100% of the women who did induce PD-L1 and subsequently received a checkpoint inhibitor are alive today."
Dr Lalezari @ 27:55 "Leronlimab has been given to 1600 patients or so, and it's been very well tolerated . . .and is not associated with any sort of dominant safety or toxicity issues . . .which is not something you can really say about any other cancer drug."
Dr Lalezari @ 28:12 "We're seeing a signal . . .retrospectively that the drug appears to be working on both triple negative breast cancer and in colorectal cancer . . and in particular , in the patients who happen to get a checkpoint inhibitor, we're seeing evidence of sustained remission. . . which is unheard of in a patient with lung and brain metastasis."
Dr Lalezari @ 28:37 "The onus on Cytodyn now . . .and the reason I feel enormous pressure everyday . . .is that we have to prospectively confirm this . . . prospectively confirm both that Leronimab is disrupting the micro environment and causing this PDL1 induction and that providing the patients with a checkpoint inhibitor provides them with significant clinical benefit. And if we do that, it's a game changer."
The host @ 29:25 "You're on the precipice here of some major things."
Dr Lalezari: "I think precipice is the right word."
30:10 re colorectal cancer study "We have a bunch of sites actively enrolling now."
31:40 glioblastoma is "a bit of a bankshot"
Finally at the end, he thanks the shareholders.
Nice to finally hear something!
31
